Literature DB >> 23427911

Models and discovery strategies for new therapies of retinoblastoma.

Samuel K Houston1, Theodore J Lampidis, Timothy G Murray.   

Abstract

INTRODUCTION: Retinoblastoma is the most common primary intraocular malignancy in children. Treatment success approaches 100% at specialized centers with globe-salvaging modalities. Primary management of retinoblastoma consists of chemoreduction with local consolidation, although newer techniques include local delivery via intra-arterial chemotherapy, periocular, or intravitreal injection. Animal models have played an integral role in the understanding of retinoblastoma tumorigenesis and have contributed to the development of globe-salvaging treatments. AREAS COVERED: This review focuses on the use of models and discovery strategies on translational research in retinoblastoma. The article reviews gene expression profiling, knockout models, and transgenic animal models. In addition, the review discusses translational applications of hyperthermia, chemotherapy (systemic and local delivery), radiation therapy, and novel targets such as hypoxia, angiogenesis, cellular metabolism, and tumor suppressor functions. EXPERT OPINION: Retinoblastoma treatment success has been driven by translational research using novel animal models and discovery strategies. Future developments require further understanding of the unique genetic events that result in tumor growth and development, as well as an understanding of the complex interactions of tumor cells with the local tumor microenvironment and how this affects tumor growth, metastasis, and response to treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427911     DOI: 10.1517/17460441.2013.772975

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  7 in total

1.  Rapamycin, an mTOR inhibitor, induced apoptosis via independent mitochondrial and death receptor pathway in retinoblastoma Y79 cell.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.

Authors:  Yan-Dong Wang; Yong-Jing Su; Jian-Ying Li; Xiang-Chao Yao; Guang-Jiang Liang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Evidence of Tumour Microenvironment and Stromal Cellular Components in Retinoblastoma.

Authors:  Rajeswari Raguraman; Sowmya Parameswaran; Jagat Rakesh Kanwar; Vikas Khetan; Pukhraj Rishi; Rupinder Kaur Kanwar; Subramanian Krishnakumar
Journal:  Ocul Oncol Pathol       Date:  2018-07-17

4.  Incidence and survival of retinoblastoma in Taiwan: a nationwide population-based study 1998-2011.

Authors:  Su-Yin Li; Solomon Chih-Cheng Chen; Ching-Fang Tsai; Shew-Meei Sheu; Jun-Jun Yeh; Chong-Bin Tsai
Journal:  Br J Ophthalmol       Date:  2015-09-14       Impact factor: 4.638

5.  Epidemiological Characteristics of Retinoblastoma in Children Attending Almouassat University Hospital, Damascus, Syria, 2012-2016

Authors:  Ahmad Al Hasan; Rashad Murad; Khaldoun Zaid; Jourjous Al Daoud; Khaled Zaid
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

Review 6.  The Role of Intraarterial Chemotherapy in the Management of Retinoblastoma.

Authors:  Aleksandra Pekacka
Journal:  J Ophthalmol       Date:  2020-01-24       Impact factor: 1.909

7.  Establishment of a novel retinoblastoma (Rb) nude mouse model by intravitreal injection of human Rb Y79 cells - comparison of in vivo analysis versus histological follow up.

Authors:  Alexander V Tschulakow; Ulrich Schraermeyer; H Peter Rodemann; Sylvie Julien-Schraermeyer
Journal:  Biol Open       Date:  2016-11-15       Impact factor: 2.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.